Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Collegium Pharmaceutical, Inc. (COLL) vs Pacira BioSciences, Inc. (PCRX)

Collegium Pharmaceutical, Inc. and Pacira BioSciences, Inc. are both Drug Manufacturers Specialty & Generic companies. Pacira BioSciences, Inc. is the larger, with a market value of $1.0B against $737.1M — 1.4× the size. Collegium Pharmaceutical, Inc. trades at the lower P/E: 14.7× against 71.8×. Collegium Pharmaceutical, Inc. grew revenue faster over the last twelve months: 14.3% against 5.71%. Collegium Pharmaceutical, Inc. has the higher net margin (5.93% vs 1.96%) and the higher return on invested capital (7.85% vs 1.58%). Across the 21 metrics below, Collegium Pharmaceutical, Inc. leads on 14 and Pacira BioSciences, Inc. on 7.

Valuation

Metric COLL PCRX Drug Manufacturers Specialty & Generic median
P/E 14.73 71.77 20.14
P/S 0.90 1.33 2.25
P/B 2.34 1.48 1.90
Price to free cash flow n/m 5.52 16.54
EV/EBITDA 4.29 12.68 12.29
EV/Sales 2.07 1.75 2.56
Earnings yield 6.79% 1.39% (2.99%)
Free cash flow yield (5.46%) 18.11% 0.00%

Profitability

Metric COLL PCRX Drug Manufacturers Specialty & Generic median
Gross margin 60.02% 79.21% 53.94%
Operating margin 19.48% 2.66% 0.00%
Net margin 5.93% 1.96% 0.00%
Free cash flow margin 40.62% 24.06% 0.00%
Return on equity 17.61% 2.05% (0.40%)
Return on assets 2.57% 1.05% (3.32%)
Return on invested capital 7.85% 1.58% 0.00%

Growth

Metric COLL PCRX Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) 14.31% 5.71% 10.01%
EPS growth (last fiscal year) (6.99%) 107.44% —
Revenue growth, 5-year CAGR 20.28% 11.07% 6.74%
Net income growth, 5-year CAGR 18.64% (45.44%) 0.00%

Health

Metric COLL PCRX Drug Manufacturers Specialty & Generic median
Debt to equity 3.50 0.54 0.05
Current ratio 1.03 5.04 2.31
Net debt to EBITDA 1.00 1.24 0.85

Dividend

Metric COLL PCRX Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.70%
Payout ratio 0.00 0.00 0.00

Size

Metric COLL PCRX Drug Manufacturers Specialty & Generic median
Market cap 737.06m 1.02b 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack